Showing 1741-1750 of 2320 results for "".
- Investigational Agents Show Benefit in Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/investigational-agents-show-benefit-in-chronic-spontaneous-urticaria/2460938/Complete control of chronic spontaneous urticaria (CSU) is associated with improvements in key HRQoL measures, such as overall quality of life, sleep interference, activity interference and work impairment, while a marked decline in these improvements to quality of life is seen among patients wit
- New Data Show Itch Reduction with Topical Roflumilast in Psoriasis and Seborrheic Dermatitishttps://practicaldermatology.com/news/new-data-show-itch-reduction-with-topical-roflumilast-in-psoriasis-and-seborrheic-dermatitis/2460937/New patient-reported outcomes data show once-daily, topical roflumilast provides significant reductions in itch. Once-daily roflumilast cream reduced both the severity and burden of itch, and improved quality of life in the DERMIS-1 and DERMIS-2 Phase 3 pivotal studies in chronic plaque psoriasis
- New Data for Galderma’s Nemolizumab Show Rapid Onset in Prurigo Nodularis and Atopic Dermatitishttps://practicaldermatology.com/news/new-data-for-galdermas-nemolizumab-show-rapid-onset-in-prurigo-nodularis-and-atopic-dermatitis/2460935/Investigational monoclonal antibody nemolizumab demonstrates rapid onset of action and significant reduction in symptoms for patients with prurigo nodularis (PN) and atopic dermatitis (AD), according to data presented at the virtual 30th EADV congress and reported by
- Data Show Continuous Response to LEO's Tralokinumab in Adults with ADhttps://practicaldermatology.com/news/data-show-continuous-response-to-leos-tralokinumab-in-adults-with-ad/2460933/After two years of continuous treatment with tralokinumab, adult patients with moderate-to-severe atopic dermatitis maintained improvements in signs and symptoms, itch severity, and sleep interference, according to interim findings from the Phase 3 ECZTEND trial presented as an oral presenta
- Bimekizumab Performs Well in Psoriasis with Results Lasting through Two Yearshttps://practicaldermatology.com/news/bimekizumab-performs-well-in-psoriasis-with-results-lasting-through-two-years/2460929/Interim results from the BE BRIGHT open-label extension (OLE) study showed clinical responses observed in bimekizumab-treated psoriasis patients during the first 16 weeks of BE SURE were sustained through to two years of treatment with continuous maintenance dosing, UCB reports. T
- Science of Skincare Summit Coming in Novemberhttps://practicaldermatology.com/news/science-of-skincare-summit-coming-in-november/2460924/Dermatologists Patti Farris, MD and Ted Lain, MD will kick off the Science of Skincare Summit November 6 at JW Marriott Essex House in New York City. The one-day event is dedicted to education on skincare for medical and aesthetic professionals in all specialties, with content delivered
- Mayne Pharma's Lexette Approved for Adolescentshttps://practicaldermatology.com/news/mayne-pharmas-lexette-approved-for-adolescents/2460921/Lexette® (halobetasol propionate) foam, 0.05% from Mayne Pharma is now approved for the treatment of plaque psoriasis in patients aged 12 years and older. FDA approved Lexette in 2018 for use in adults. Approval in adolescents is
- New Publication Supports Diagnostic Value of DermTech's PLAhttps://practicaldermatology.com/news/new-publication-supports-diagnostic-value-of-dermtechs-pla/2460914/Evaluation of genomic atypia with DermTech’s Pigmented Lesion Assay (PLA) increases both the real-world negative predictive value (NPV) and positive predictive value (PPV) of the melanoma diagnostic pathway and reduces biopsy burden, relative to the current visual assessment and histopathol
- New Global Initiative Aims to Improve Eczema Carehttps://practicaldermatology.com/news/new-global-initiative-aims-to-improve-eczema-care/2460913/The new Global Patient Initiative to Improve Eczema Care (GPIIEC) is a global collaboration to establish a common "yardstick" to assess the responsiveness of health systems to the needs of patients with eczema and their caregivers. The global
- World Atopic Eczema Day Focuses on Disease Awarenesshttps://practicaldermatology.com/news/world-atopic-eczema-day-focuses-on-disease-awareness/2460912/As patient communities worldwide join forces to raise awareness about atopic eczema, the International Alliance of Dermatology Patient Organisations (GlobalSkin) and the global atopic eczema community call on healthcare professionals, health policy decision ma